ESSA Pharma Inc.

NasdaqCM EPIX

ESSA Pharma Inc. Market Capitalization on January 14, 2025: USD 78.57 M

ESSA Pharma Inc. Market Capitalization is USD 78.57 M on January 14, 2025, a -80.53% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

ESSA Pharma Inc. 52-week high Market Capitalization is USD 470.22 M on February 07, 2024, which is 498.49% above the current Market Capitalization.
ESSA Pharma Inc. 52-week low Market Capitalization is USD 62.14 M on November 01, 2024, which is -20.90% below the current Market Capitalization.
ESSA Pharma Inc. average Market Capitalization for the last 52 weeks is USD 253.51 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: EPIX

ESSA Pharma Inc.

CEO	Dr. David Ross Parkinson M.D.
IPO Date	March 13, 2015
Location	Canada
Headquarters	999 West Broadway
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years